• The Company remains focused on seeking additional funding to execute its strategic plan in rare diseases
• Exclusive discussions with a leading investor to monetize royalties from sales of TWYMEEG® (Imeglimin) in Japan
• Advanced discussions with several potential partners for each of Poxel’s three proprietary products: Imeglimin, PXL065 and PXL770
• New savings plan, including a significant reduction in workforce, in order to adapt resources to the current needs of the Company pending the relaunch of its research and development activities
• Financing horizon until March 2024 including only the tranches already drawn or fully available from the equity financing line set up with IRIS
LYON, France, December 21, 2023 – POXEL SA (Euronext: POXEL – FR0012432516), clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases , takes stock of its activities.
To receive information from POXEL in real time, send a request to [email protected].